---
title: "Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249549309.md"
description: "Wolwo Pharma announced that it has completed the clinical trial of the \"Artemisia Annua Pollen Allergen Sublingual Drops.\" The summary report indicates that the product has good safety in adult patients with allergic rhinitis, with the main adverse reactions being grade 1 and 2. After 2 years of treatment and monitoring after discontinuation, it has been confirmed that the drug effectively improves symptoms caused by Artemisia Annua/Artemisia Pollen and reduces the use of symptomatic medications, providing evidence for long-term clinical application"
datetime: "2025-07-22T09:42:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249549309.md)
  - [en](https://longbridge.com/en/news/249549309.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249549309.md)
generator: "portal-rs"
---

# Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launch

According to the Zhitong Finance APP, Wolwo Pharma (300357.SZ) announced that its product "Artemisia Annua Pollen Allergen Sublingual Drops" (hereinafter referred to as "the product") has completed the "Long-term Efficacy and Safety Evaluation of Artemisia Annua Pollen Allergen Sublingual Drops in Adult Patients with Allergic Rhinitis - A Multicenter, Open-label Clinical Trial" and has formed a clinical trial summary report.

The safety analysis results of this clinical trial showed good safety, with the severity of adverse reactions mainly at levels 1 and 2. The types of adverse reactions were highly consistent with the adult phase III clinical safety data of the product and the adverse reaction data in the drug instructions.

This clinical trial verified that the Artemisia Annua Pollen Allergen Sublingual Drops can effectively improve the symptoms of allergic rhinitis (or accompanied by conjunctivitis) caused by Artemisia Annua/Artemisia vulgaris pollen through a 2-year treatment and efficacy monitoring during the first pollen season after discontinuation, and reduce the use of symptomatic medications. This trial further revealed the sustained efficacy improvement during the long-term treatment process and the maintenance of efficacy after discontinuation, providing sufficient evidence for the clinical long-term application of the drug

### Related Stocks

- [300357.CN](https://longbridge.com/en/quote/300357.CN.md)

## Related News & Research

- [16:30 ETChase Corporation Acquires Hylomar](https://longbridge.com/en/news/296826262.md)
- [LibertyStream reports three months of battery-grade lithium carbonate output at 99.7%+ purity](https://longbridge.com/en/news/296788400.md)
- [Cocoa Prices Fall on Rising Nigerian Cocoa Exports](https://longbridge.com/en/news/296637826.md)
- [SalMar – Record-strong biological performance](https://longbridge.com/en/news/296859687.md)
- [Danantara Sumberdaya Indonesia is identifying commodity export inconsistencies, chief says](https://longbridge.com/en/news/296773364.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**